Listed

Ligand Pharmaceuticals Inc

LGNDNasdaqCIK 886163HealthcareFiscal year ends Dec 31

Latest reported revenue, Q2 FY2026$63.7mRevenue, Q2 FY2026, three months to 2026-06-30$63.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-07, accession 0000886163-26-000044.Report this figureThree months to Jun 30, 2026, from the 10-Q filed Aug 7, 2026.

Latest quarter: Q2 FY2026

Three months to Jun 30, 2026, against the same quarter a year earlier.

  • Revenue$63.7mRevenue, Q2 FY2026, three months to 2026-06-30$63.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-07, accession 0000886163-26-000044.Report this figure+33.7% on a year earlier
  • Gross marginnot reported (Gross profit not reported)No year-earlier figure to compare
  • Operating margin13.5%Operating margin, Q2 FY2026, three months to 2026-06-30. operating income / revenueOperating income: $8.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-07, accession 0000886163-26-000044.Revenue: $63.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-07, accession 0000886163-26-000044.Report this figure−4.2 pts on a year earlier
  • Net margin76.2%Net margin, Q2 FY2026, three months to 2026-06-30. net income / revenueNet income: $48.5m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-07, accession 0000886163-26-000044.Revenue: $63.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-07, accession 0000886163-26-000044.Report this figure+66.0 pts on a year earlier
  • Diluted EPS$2.22Diluted EPS, Q2 FY2026, three months to 2026-06-30$2.22 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-07, accession 0000886163-26-000044.Report this figure+825.0% on a year earlier
  • Free cash flow$24.0mFree cash flow, Q2 FY2026, three months to 2026-06-30. operating cash flow − capital expenditureOperating cash flow: $24.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-07, accession 0000886163-26-000044. Derived: 6-month figure less the 3-month figure.Capital expenditure: $26.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-07, accession 0000886163-26-000044. Derived: 6-month figure less the 3-month figure.Report this figure+53.9% on a year earlier

Last eight quarters

Full statements
Revenue$63.7mOperating margin 13.5%
Diluted EPS$2.22, Q2 FY2026
Free cash flow$24.0m, Q2 FY2026
Ligand Pharmaceuticals Inc, key figures for the last eight quarters
Line itemUnitQ3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30Shape over the periods
Revenue$m51.8Revenue, Q3 FY2024, three months to 2024-09-30$51.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-07, accession 0000886163-25-000063.Report this figure42.8Revenue, Q4 FY2024, three months to 2024-12-31$42.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-27, accession 0000886163-26-000006. Derived: 12-month figure less the 9-month figure.Report this figure45.3Revenue, Q1 FY2025, three months to 2025-03-31$45.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-08, accession 0000886163-26-000034.Report this figure47.6Revenue, Q2 FY2025, three months to 2025-06-30$47.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-07, accession 0000886163-26-000044.Report this figure115Revenue, Q3 FY2025, three months to 2025-09-30$115.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-07, accession 0000886163-25-000063.Report this figure59.7Revenue, Q4 FY2025, three months to 2025-12-31$59.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-27, accession 0000886163-26-000006. Derived: 12-month figure less the 9-month figure.Report this figure51.7Revenue, Q1 FY2026, three months to 2026-03-31$51.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-08, accession 0000886163-26-000034.Report this figure63.7Revenue, Q2 FY2026, three months to 2026-06-30$63.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-07, accession 0000886163-26-000044.Report this figure
Gross margin%not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)
Operating margin%6.1%Operating margin, Q3 FY2024, three months to 2024-09-30. operating income / revenueOperating income: $3.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-07, accession 0000886163-25-000063.Revenue: $51.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-07, accession 0000886163-25-000063.Report this figure(22.5%)Operating margin, Q4 FY2024, three months to 2024-12-31. operating income / revenueOperating income: −$9.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-27, accession 0000886163-26-000006. Derived: 12-month figure less the 9-month figure.Revenue: $42.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-27, accession 0000886163-26-000006. Derived: 12-month figure less the 9-month figure.Report this figure(79.9%)Operating margin, Q1 FY2025, three months to 2025-03-31. operating income / revenueOperating income: −$36.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-08, accession 0000886163-26-000034.Revenue: $45.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-08, accession 0000886163-26-000034.Report this figure17.7%Operating margin, Q2 FY2025, three months to 2025-06-30. operating income / revenueOperating income: $8.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-07, accession 0000886163-26-000044.Revenue: $47.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-07, accession 0000886163-26-000044.Report this figure47.6%Operating margin, Q3 FY2025, three months to 2025-09-30. operating income / revenueOperating income: $54.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-07, accession 0000886163-25-000063.Revenue: $115.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-07, accession 0000886163-25-000063.Report this figure23.2%Operating margin, Q4 FY2025, three months to 2025-12-31. operating income / revenueOperating income: $13.8m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-27, accession 0000886163-26-000006. Derived: 12-month figure less the 9-month figure.Revenue: $59.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-27, accession 0000886163-26-000006. Derived: 12-month figure less the 9-month figure.Report this figure33.6%Operating margin, Q1 FY2026, three months to 2026-03-31. operating income / revenueOperating income: $17.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-08, accession 0000886163-26-000034.Revenue: $51.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-08, accession 0000886163-26-000034.Report this figure13.5%Operating margin, Q2 FY2026, three months to 2026-06-30. operating income / revenueOperating income: $8.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-07, accession 0000886163-26-000044.Revenue: $63.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-07, accession 0000886163-26-000044.Report this figure
Net margin%(13.8%)Net margin, Q3 FY2024, three months to 2024-09-30. net income / revenueNet income: −$7.2m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-07, accession 0000886163-25-000063.Revenue: $51.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-07, accession 0000886163-25-000063.Report this figure(72.6%)Net margin, Q4 FY2024, three months to 2024-12-31. net income / revenueNet income: −$31.1m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-27, accession 0000886163-26-000006. Derived: 12-month figure less the 9-month figure.Revenue: $42.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-27, accession 0000886163-26-000006. Derived: 12-month figure less the 9-month figure.Report this figure(93.6%)Net margin, Q1 FY2025, three months to 2025-03-31. net income / revenueNet income: −$42.5m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-05-08, accession 0000886163-26-000034.Revenue: $45.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-08, accession 0000886163-26-000034.Report this figure10.2%Net margin, Q2 FY2025, three months to 2025-06-30. net income / revenueNet income: $4.8m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-07, accession 0000886163-26-000044.Revenue: $47.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-07, accession 0000886163-26-000044.Report this figure101.6%Net margin, Q3 FY2025, three months to 2025-09-30. net income / revenueNet income: $117.3m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-07, accession 0000886163-25-000063.Revenue: $115.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-07, accession 0000886163-25-000063.Report this figure75.1%Net margin, Q4 FY2025, three months to 2025-12-31. net income / revenueNet income: $44.8m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-27, accession 0000886163-26-000006. Derived: 12-month figure less the 9-month figure.Revenue: $59.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-27, accession 0000886163-26-000006. Derived: 12-month figure less the 9-month figure.Report this figure(25.8%)Net margin, Q1 FY2026, three months to 2026-03-31. net income / revenueNet income: −$13.3m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-07, accession 0000886163-26-000044.Revenue: $51.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-08, accession 0000886163-26-000034.Report this figure76.2%Net margin, Q2 FY2026, three months to 2026-06-30. net income / revenueNet income: $48.5m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-07, accession 0000886163-26-000044.Revenue: $63.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-07, accession 0000886163-26-000044.Report this figure
Diluted EPS$ per share(0.39)Diluted EPS, Q3 FY2024, three months to 2024-09-30−$0.39 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-07, accession 0000886163-25-000063.Report this figurenot reported (Diluted EPS not reported)(2.21)Diluted EPS, Q1 FY2025, three months to 2025-03-31−$2.21 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-08, accession 0000886163-26-000034.Report this figure0.24Diluted EPS, Q2 FY2025, three months to 2025-06-30$0.24 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-07, accession 0000886163-26-000044.Report this figure5.68Diluted EPS, Q3 FY2025, three months to 2025-09-30$5.68 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-07, accession 0000886163-25-000063.Report this figurenot reported (Diluted EPS not reported)(0.67)Diluted EPS, Q1 FY2026, three months to 2026-03-31−$0.67 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-08, accession 0000886163-26-000034.Report this figure2.22Diluted EPS, Q2 FY2026, three months to 2026-06-30$2.22 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-07, accession 0000886163-26-000044.Report this figure
Free cash flow$m35.9Free cash flow, Q3 FY2024, three months to 2024-09-30. operating cash flow − capital expenditureOperating cash flow: $36.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-07, accession 0000886163-25-000063. Derived: 9-month figure less the 6-month figure.Capital expenditure: $596.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-07, accession 0000886163-25-000063. Derived: 9-month figure less the 6-month figure.Report this figure27.8Free cash flow, Q4 FY2024, three months to 2024-12-31. operating cash flow − capital expenditureOperating cash flow: $28.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-27, accession 0000886163-26-000006. Derived: 12-month figure less the 9-month figure.Capital expenditure: $712.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-27, accession 0000886163-26-000006. Derived: 12-month figure less the 9-month figure.Report this figure(25.7)Free cash flow, Q1 FY2025, three months to 2025-03-31. operating cash flow − capital expenditureOperating cash flow: −$25.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-08, accession 0000886163-26-000034.Capital expenditure: $214.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-08, accession 0000886163-26-000034.Report this figure15.6Free cash flow, Q2 FY2025, three months to 2025-06-30. operating cash flow − capital expenditureOperating cash flow: $15.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-07, accession 0000886163-26-000044. Derived: 6-month figure less the 3-month figure.Capital expenditure: $214.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-07, accession 0000886163-26-000044. Derived: 6-month figure less the 3-month figure.Report this figure13.1Free cash flow, Q3 FY2025, three months to 2025-09-30. operating cash flow − capital expenditureOperating cash flow: $13.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-07, accession 0000886163-25-000063. Derived: 9-month figure less the 6-month figure.Capital expenditure: $15.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-07, accession 0000886163-25-000063. Derived: 9-month figure less the 6-month figure.Report this figure45.9Free cash flow, Q4 FY2025, three months to 2025-12-31. operating cash flow − capital expenditureOperating cash flow: $45.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-27, accession 0000886163-26-000006. Derived: 12-month figure less the 9-month figure.Capital expenditure: $9.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-27, accession 0000886163-26-000006. Derived: 12-month figure less the 9-month figure.Report this figure48.5Free cash flow, Q1 FY2026, three months to 2026-03-31. operating cash flow − capital expenditureOperating cash flow: $48.7m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-08, accession 0000886163-26-000034.Capital expenditure: $228.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-08, accession 0000886163-26-000034.Report this figure24.0Free cash flow, Q2 FY2026, three months to 2026-06-30. operating cash flow − capital expenditureOperating cash flow: $24.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-07, accession 0000886163-26-000044. Derived: 6-month figure less the 3-month figure.Capital expenditure: $26.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-07, accession 0000886163-26-000044. Derived: 6-month figure less the 3-month figure.Report this figure

Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.

Last five fiscal years

Revenue$268.1mOperating margin 15.3%
Diluted EPS$6.13, FY2025
Free cash flow$48.9m, FY2025
Ligand Pharmaceuticals Inc, key figures for the last five fiscal years
Line itemUnitFY20212021-12-31FY20222022-12-31FY20232023-12-31FY20242024-12-31FY20252025-12-31Shape over the periods
Revenue$m242Revenue, FY2021, twelve months to 2021-12-31$241.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2024-02-29, accession 0000886163-24-000009.Report this figure196Revenue, FY2022, twelve months to 2022-12-31$196.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-02-28, accession 0000886163-25-000012.Report this figure131Revenue, FY2023, twelve months to 2023-12-31$131.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-27, accession 0000886163-26-000006.Report this figure167Revenue, FY2024, twelve months to 2024-12-31$167.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-27, accession 0000886163-26-000006.Report this figure268Revenue, FY2025, twelve months to 2025-12-31$268.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-27, accession 0000886163-26-000006.Report this figure
Gross margin%not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)
Operating margin%43.0%Operating margin, FY2021, twelve months to 2021-12-31. operating income / revenueOperating income: $103.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2024-02-29, accession 0000886163-24-000009.Revenue: $241.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2024-02-29, accession 0000886163-24-000009.Report this figure1.5%Operating margin, FY2022, twelve months to 2022-12-31. operating income / revenueOperating income: $3.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2025-02-28, accession 0000886163-25-000012.Revenue: $196.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-02-28, accession 0000886163-25-000012.Report this figure9.1%Operating margin, FY2023, twelve months to 2023-12-31. operating income / revenueOperating income: $11.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-27, accession 0000886163-26-000006.Revenue: $131.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-27, accession 0000886163-26-000006.Report this figure(13.5%)Operating margin, FY2024, twelve months to 2024-12-31. operating income / revenueOperating income: −$22.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-27, accession 0000886163-26-000006.Revenue: $167.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-27, accession 0000886163-26-000006.Report this figure15.3%Operating margin, FY2025, twelve months to 2025-12-31. operating income / revenueOperating income: $41.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-27, accession 0000886163-26-000006.Revenue: $268.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-27, accession 0000886163-26-000006.Report this figure
Net margin%23.7%Net margin, FY2021, twelve months to 2021-12-31. net income / revenueNet income: $57.1m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2024-02-29, accession 0000886163-24-000009.Revenue: $241.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2024-02-29, accession 0000886163-24-000009.Report this figure(17.0%)Net margin, FY2022, twelve months to 2022-12-31. net income / revenueNet income: −$33.4m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2025-02-28, accession 0000886163-25-000012.Revenue: $196.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-02-28, accession 0000886163-25-000012.Report this figure39.7%Net margin, FY2023, twelve months to 2023-12-31. net income / revenueNet income: $52.2m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-27, accession 0000886163-26-000006.Revenue: $131.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-27, accession 0000886163-26-000006.Report this figure(2.4%)Net margin, FY2024, twelve months to 2024-12-31. net income / revenueNet income: −$4.0m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-27, accession 0000886163-26-000006.Revenue: $167.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-27, accession 0000886163-26-000006.Report this figure46.4%Net margin, FY2025, twelve months to 2025-12-31. net income / revenueNet income: $124.5m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-27, accession 0000886163-26-000006.Revenue: $268.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-27, accession 0000886163-26-000006.Report this figure
Diluted EPS$ per share3.31Diluted EPS, FY2021, twelve months to 2021-12-31$3.31 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2024-02-29, accession 0000886163-24-000009.Report this figure(1.98)Diluted EPS, FY2022, twelve months to 2022-12-31−$1.98 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2025-02-28, accession 0000886163-25-000012.Report this figure2.94Diluted EPS, FY2023, twelve months to 2023-12-31$2.94 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-02-27, accession 0000886163-26-000006.Report this figure(0.22)Diluted EPS, FY2024, twelve months to 2024-12-31−$0.22 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-02-27, accession 0000886163-26-000006.Report this figure6.13Diluted EPS, FY2025, twelve months to 2025-12-31$6.13 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-02-27, accession 0000886163-26-000006.Report this figure
Free cash flow$m70.0Free cash flow, FY2021, twelve months to 2021-12-31. operating cash flow − capital expenditureOperating cash flow: $78.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2024-02-29, accession 0000886163-24-000009.Capital expenditure: $8.8m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2024-02-29, accession 0000886163-24-000009.Report this figure120Free cash flow, FY2022, twelve months to 2022-12-31. operating cash flow − capital expenditureOperating cash flow: $137.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2025-02-28, accession 0000886163-25-000012.Capital expenditure: $17.9m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2025-02-28, accession 0000886163-25-000012.Report this figure46.1Free cash flow, FY2023, twelve months to 2023-12-31. operating cash flow − capital expenditureOperating cash flow: $49.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-27, accession 0000886163-26-000006.Capital expenditure: $3.5m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-27, accession 0000886163-26-000006.Report this figure95.2Free cash flow, FY2024, twelve months to 2024-12-31. operating cash flow − capital expenditureOperating cash flow: $97.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-27, accession 0000886163-26-000006.Capital expenditure: $1.8m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-27, accession 0000886163-26-000006.Report this figure48.9Free cash flow, FY2025, twelve months to 2025-12-31. operating cash flow − capital expenditureOperating cash flow: $49.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-27, accession 0000886163-26-000006.Capital expenditure: $452.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-27, accession 0000886163-26-000006.Report this figure

Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.

Insider purchases and sales

All insider transactions

The last 20 open-market transactions reported on Form 4 (codes P and S). The reported price is the price per share the insider stated on the form: filing data, not a market price.

No open-market purchases or sales by insiders are in coverage from Nov 2024 to Oct 2026.

No open-market purchases or sales by insiders are in coverage for this company.

Funds that report holding it

All funds

From each manager's latest Form 13F, largest reported value first. Reported value is as filed at the quarter end: filing data, not a price. A put or call is an option position, not shares held.

Funds that report holding Ligand Pharmaceuticals Inc
FundQuarter endedReported valueSharesPut or callChange on the quarter before
BlackRock, Inc.2026-06-30$980.2m3,100,996Added+139,073
Invesco Ltd.2026-06-30$379.8m1,201,644Added+378,040
VANGUARD PORTFOLIO MANAGEMENT LLC2026-06-30$359.8m1,138,316Added+38,049
Jupiter Topco LLC2026-06-30$328.9m1,040,578Not compared
VANGUARD CAPITAL MANAGEMENT LLC2026-06-30$275.3m870,950Added+22,861
STATE STREET CORP2026-06-30$261.3m826,539Added+47,683
FMR LLC2026-06-30$241.1m762,827Added+166,700
FRANKLIN RESOURCES INC2026-06-30$237.7m752,044Added+178,867
CONGRESS ASSET MANAGEMENT CO2026-06-30$208.6m659,911Added+155,274
JANUS HENDERSON GROUP PLC2026-03-31$201.6m1,009,891Not compared

Recent filings

All 1,606 filings

Reports and events: 10-K, 10-Q, 8-K, proxy statements and ownership schedules.

Ligand Pharmaceuticals Inc, recent filings
FiledFormWhat it isAccession number
2026-10-2907:14 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0000886163-26-000058
2026-09-2407:15 ET8-K7.01 Regulation FD disclosure; 8.01 Other events0000886163-26-000054
2026-09-2207:08 ET8-K7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0000886163-26-000050
2026-09-0216:08 ET8-K/A9.01 Financial statements and exhibits0000886163-26-000048
2026-08-0716:06 ET10-QQuarterly reportPeriod 2026-06-300000886163-26-000044
2026-08-0607:05 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0000886163-26-000041
2026-07-1409:20 ET8-K1.01 Entry into a material agreement; 2.01 Completion of an acquisition or disposition; 2.03 New direct financial obligation; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0001193125-26-302660
2026-06-2517:00 ET8-K1.01 Entry into a material agreement; 2.03 New direct financial obligation; 3.02 Unregistered sale of equity; 8.01 Other events; 9.01 Financial statements and exhibits0001193125-26-282990
2026-06-2207:11 ET8-K1.01 Entry into a material agreement; 8.01 Other events; 9.01 Financial statements and exhibits0001193125-26-276694
2026-06-0916:02 ET8-K5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results0000886163-26-000038

Latest annual report

Form 10-K for the fiscal year ended Dec 31, 2025Filed Feb 27, 2026. Its page lists the documents and the extracted sections, such as Business and Risk factors.

Forecast league

Q3 FY2026, the quarter ended 2026-09-30, locked when the 8-K was accepted. It is scored when the 10-Q or 10-K is ingested.See the target

About the filer

CIK
886163
Tickers
LGND, LGNDZ, LGNXZ, LGNYZ, LGNZZ
Exchange
Nasdaq
SIC code
2834 Pharmaceutical Preparations
Sector
Healthcare
Fiscal year ends
Dec 31
Incorporated in
DE
Filer category
Large accelerated filer
Former names
LIGAND PHARMACEUTICALS (to 1994-09-13)

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 29, 2026, 07:16 ET. Listed shows no prices and gives no investment advice.